Table 1. Correlations between CD4⁺ and CD8⁺ T cell numbers, CD4/CD8 ratio, and clinicopathologic characteristics in breast cancer patients (n=81).

	CD4			CD8			CD4/CD8
	≤16	＞16	P	≤13	＞13	P	≤1.2	＞1.2	P
Age
<60 years	23	18		14	25		21	20
≥60 years	24	15	0.79	21	20	0.25	18	21	0.82
Tumor stage
I	27	3		7	23		24	6
II	15	15		15	15		10	20
III	6	15	2.75×10−5	13	8	0.02	6	15	1.25 ×10−4
Tumor size
<2.1 cm	30	11		15	24		25	16
≥2.1 cm	17	22	0.01	20	21	0.48	14	25	0.04
Nodal status
Negative	32	10		11	31		29	13
positive	16	23	0.003	24	15	2.84×10−3	11	28	5.58 ×10−4
ER status
Negative	11	12		7	16		9	14
Positive	37	21	0.28	28	30	0.23	31	27	0.36
HER2
High	13	9		11	11		11	11
Low	28	15		15	28		24	19
Negative	2	8	0.03	6	4	0.25	2	8	0.12
Relapse-freeSurvival
No-recurrance	38	17		12	35		35	20
Recurrence	7	10	0.07	15	19	2.67×10−5	2	15	5.35 ×10−4
Overall Survival
Alive	37	19		17	39		34	22
Died	11	14	0.11	18	7	1.14 ×10−3	6	19	4.92 ×10−3

Note: Evaluated by χ2 test. Abbreviations: ER, estrogen receptor; HER2, human epidermal growth factor receptor 2. Boldface indicates the significance of the p value.